We assessed the safety of PD-1/PD-L1 inhibitor blockade based on data from about a dozen clinical trials (Table 2) to show that PD-1/PD-L1 blockade provided a similar and accepted safety profile for advanced-HCC patients vs. those with other malignant tumors. The gene discussed is PDCD1; the disease is cancer.